Deutsche Bank AG Cuts Position in Stoke Therapeutics, Inc. $STOK

Key Points

• Deutsche Bank AG significantly reduced its stake in Stoke Therapeutics by 92.7%, selling 325,048 shares, resulting in a remaining ownership of 25,566 shares valued at approximately $170,000.
• Multiple hedge funds have taken new positions in Stoke Therapeutics, with Toronto Dominion Bank investing $35 million and RTW Investments LP increasing its stake by 10.1%, now holding shares valued at over $56 million.
• The stock has received favorable ratings from several brokerages, with a consensus buy rating and an average target price of $25.57, showing strong investor confidence in its growth potential.

Deutsche Bank AG reduced its position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 92.7% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 25,566 shares of the company's stock after selling 325,048 shares during the period. Deutsche Bank AG's holdings in Stoke Therapeutics were worth $170,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC boosted its stake in Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after purchasing an additional 5,084 shares in the last quarter. US Bancorp DE increased its holdings in shares of Stoke Therapeutics by 9,743.9% during the 1st quarter. US Bancorp DE now owns 11,222 shares of the company's stock valued at $75,000 after purchasing an additional 11,108 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock valued at $132,000 after purchasing an additional 4,918 shares in the last quarter. Invesco Ltd. purchased a new stake in Stoke Therapeutics in the 4th quarter worth $133,000. Finally, Net Worth Advisory Group purchased a new stake in Stoke Therapeutics in the 1st quarter worth $138,000.

Stoke Therapeutics Stock Performance

Shares of STOK stock traded up $0.18 on Wednesday, hitting $19.77. 1,287,856 shares of the stock traded hands, compared to its average volume of 810,398. The firm's 50-day moving average price is $14.42 and its two-hundred day moving average price is $10.83. Stoke Therapeutics, Inc. has a twelve month low of $5.35 and a twelve month high of $20.45. The stock has a market capitalization of $1.08 billion, a PE ratio of 23.26 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. The company had revenue of $13.82 million for the quarter, compared to analysts' expectations of $31.51 million. On average, equities research analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 13,712 shares of the company's stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $15.00, for a total value of $205,680.00. Following the transaction, the general counsel owned 19,631 shares of the company's stock, valued at $294,465. This represents a 41.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Barry Ticho sold 4,504 shares of the company's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $12.82, for a total transaction of $57,741.28. Following the completion of the transaction, the insider directly owned 16,775 shares in the company, valued at $215,055.50. The trade was a 21.17% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 9.50% of the company's stock.

Wall Street Analysts Forecast Growth

STOK has been the subject of several recent analyst reports. Needham & Company LLC reissued a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Wedbush upped their target price on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a report on Wednesday, August 13th. Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. BTIG Research set a $28.00 target price on shares of Stoke Therapeutics and gave the stock a "buy" rating in a report on Monday, August 18th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $25.57.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.